Batalini F, Gulhan DC, Mao V, Tran A, et al. Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers. Clin Cancer Res 2022 Sep 1. pii: 708955. doi: 10.1158/1078-0432.CCR-22-0749.
PMID: 36048535